Comparison of Intramuscular Dose of Progesterone with Oral Progesterone in Heavy Menstrual Bleeding

Objective: To compare the efficacy of oral and intramuscular progesterone in women with heavy menstrual bleeding presenting at tertiary care hospital. Methodology: The aim of this investigation was to rigorously assess the comparative impacts of oral versus intramuscular administration of progesterone in a cohort of females aged 18 to 49 experiencing significant menstrual hemorrhage; this study was undertaken at the Department of Obstetrics and Gynaecology, Sheikh Zayed Woman Hospital, SMBBMU, Larkana, during the period from November, 2024 to April, 2025. Subjects were systematically assigned to receive either oral or intramuscular progesterone through a randomized protocol across three distinct cycles. The assessment of therapeutic efficacy was performed at the three-month interval. The data obtained were analyzed through the software SPSS version 26.0, considering P ≤ 0.05 as significant. Results: The average age of the subjects was 31.13 ± 7.85 years in the oral administration group, and 32.81 ± 7.56 years in the intramuscular group. The therapeutic effectiveness was observed in 37.7% of females who were given oral progesterone, in contrast to just 15.1% of those who were treated with intramuscular progesterone. This observed variance was determined to be statistically significant (p = 0.008). Conclusion: Current findings reveal that oral progesterone shows significantly enhanced effectiveness relative to intramuscular progesterone in addressing menorrhagia among women within the reproductive age group. In light of its superior effectiveness and convenient administration, oral progesterone ought to be regarded as a preferential therapeutic modality. These results furnish empirically supported guidance for the judicious selection of the most advantageous route of progesterone therapy within clinical practice.